Oh. I was confused about the approval rejections. I see now the rejections are accomodating MSB. And anyway, as you have stated, the whole FDA attending MOA conferences is much better than Approving anything.
And I see all those failed primary end points were only there to allow secondary end points to shine on through.
I like your positivity. I bet you would say a gangrenous toe would be fabulous as there’s no need to cut your toenails.
Where is Novartis?, page-122
-
- There are more pages in this discussion • 1,395 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |